- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06142656
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome
November 26, 2023 updated by: engy wahsh, October 6 University
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome: A Randomized Clinical Trial
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: ahmed hussein
- Email: ahmedhussein.med@o6u.edu.eg
Study Contact Backup
- Name: ahmed hussein, phD
- Phone Number: 01001749605
- Email: ahmedhussein.med@o6u.edu.eg
Study Locations
-
-
-
Giza, Egypt, 12585
- Recruiting
- October 6 university hospital
-
Contact:
- ahmed M. A, phD
- Phone Number: 01001749605
-
Contact:
- Hanan elhanafy
- Phone Number: 01281084864
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
-Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.
Exclusion Criteria:
- Patients with history of diabetes mellitus (Type 1 or 2).
- Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months
- Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors
- Eating disorders (anorexia, bulimia) or gastrointestinal disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Metformin
|
Metformin Hydrochloride 850 mg oral tablet
|
Active Comparator: Vildagliptin
|
Vildagliptin 50 MG oral tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of luteinizing hormone (LH)
Time Frame: at baseline and after 3 months
|
serum luteinizing hormone (LH)
|
at baseline and after 3 months
|
Concentration of Follicle-stimulating hormone
Time Frame: at baseline and after 3 months
|
Serum Follicle-stimulating hormone
|
at baseline and after 3 months
|
Concentration of Free androgen index
Time Frame: at baseline and after 3 months
|
serum Free androgen index
|
at baseline and after 3 months
|
Concentration of total testosterone
Time Frame: at baseline and after 3 months
|
serum total testosterone
|
at baseline and after 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: ahmed hussein, PhD, October 6 university hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 25, 2023
Primary Completion (Estimated)
April 1, 2024
Study Completion (Estimated)
May 1, 2024
Study Registration Dates
First Submitted
November 13, 2023
First Submitted That Met QC Criteria
November 16, 2023
First Posted (Actual)
November 21, 2023
Study Record Updates
Last Update Posted (Actual)
November 29, 2023
Last Update Submitted That Met QC Criteria
November 26, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Endocrine System Diseases
- Disease
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Syndrome
- Ovarian Cysts
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Metformin
- Vildagliptin
Other Study ID Numbers
- PRC-Ph-2307004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Poly Cystic Ovary Syndrome
-
Chemical ResourcesCompletedPoly Cystic Ovary Syndrome
-
Allied Hospital FaisalabadCompleted
-
Benha UniversityCompletedInfertility Poly Cystic Ovary
-
Sohag UniversityRecruitingPoly Cystic Ovary Treatment for InfertilityEgypt
-
Ain Shams UniversityNot yet recruiting
-
Alexandria UniversityRecruitingPolycystic Ovary Syndrome (PCOS)Egypt
-
Saudi German Hospital - MadinahCompletedPolycystic Ovary Syndrome (PCOS)Saudi Arabia
-
Poznan University of Medical SciencesUniversity of California, DavisUnknownPolycystic Ovary Syndrome (PCOS)Poland
-
Riphah International UniversityCompleted
-
Dexa Medica GroupCompletedPolycystic Ovary Syndrome (PCOS)Indonesia
Clinical Trials on Metformin Hydrochloride tablet
-
Haisco Pharmaceutical Group Co., Ltd.The Fourth Hospital of Hebei Medical UniversityRecruitingDiabetic Neuropathies | Diabetic Neuropathy PeripheralChina
-
British Columbia Cancer AgencyBC Cancer Foundation; Pancreatic Cancer CanadaUnknownResectable Pancreatic Ductal AdenocarcinomaCanada
-
University Health Network, TorontoActive, not recruiting
-
Mayo ClinicNational Institute on Aging (NIA)CompletedObesity | Insulin Resistance | Obesity, AbdominalUnited States
-
Universiteit AntwerpenUniversity Hospital, AntwerpActive, not recruiting
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Unknown
-
University Hospital, AntwerpHasselt University; University Hospital, Ghent; AZ Sint-Jan AV; National MS Center... and other collaboratorsRecruitingMultiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary-progressive Multiple SclerosisBelgium
-
Rajavithi HospitalCompletedMetformin | CA EndometriumThailand
-
Cairo UniversityUnknown
-
Copenhagen University Hospital at HerlevNot yet recruiting